PharmiWeb.com - Global Pharma News & Resources

Healthcare - Press Releases

Date Title Company
01-May-2024 SIRIO to launch PureOrganixTM range of gummies and softgels at Vitafoods Europe 2024 CPHI North America
01-May-2024 CPHI North America experts ‘mid-sized domestic CDMOs need to invest in operational efficiencies to drive “real” reshoring’ CPHI North America
01-May-2024 Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health Viatris
30-Apr-2024 Bioscript Group acquires Enzyme Communications to bolster its medical writing, scientific content creation and storytelling capabilities Bioscript Group
30-Apr-2024 Transformative partnership between the Medicines Patent Pool and ViiV Healthcare enables 24 million people in low- and middle-income countries to access innovative HIV treatment ViiV Healthcare
30-Apr-2024 Digital Pharmaceutical Supply Chain Management Market Size To Reach $1.84Bn By 2030 Grand View Research
26-Apr-2024 OncoZenge Releases Paper on BupiZenge™ Addressing Unmet Medical Needs OncoZenge
26-Apr-2024 Liebherr presents its innovative cooling solutions at Clinical Pharmacy Congress 2024 Liebherr
26-Apr-2024 eyeDNA Therapeutics to Present 2-year Follow-up Phase I/II Data on its Investigational Gene Therapy HORA-PDE6b for Retinitis Pigmentosa at the ARVO 2024 Annual Meeting eyeDNA Therapeutics
25-Apr-2024 Lindus Health Debuts "All-in-One Diagnostics CRO" Solution for Diagnostic Clinical Trials Lindus Health
25-Apr-2024 New £40M research centres will unlock new tests, treatments and cures for people living with rare diseases LifeArc
25-Apr-2024 Potentially fatal anaemia cases are on the rise – watch out for lesser-known signs, urges expert London Medical Laboratory
25-Apr-2024 Cell Culture Media Market Size to Worth Nearly USD 18.50 Bn by 2033 Precedence Research
24-Apr-2024 InnoScot Health backs World IP Day aim of ‘building common future’ through innovation InnoScot Health
23-Apr-2024 CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy Janssen-Cilag International NV,
23-Apr-2024 BenevolentAI provides an update on its business priorities BenevolentAI
23-Apr-2024 Cambridge Cognition spin-out Monument Therapeutics accesses £1.5m for schizophrenia clinical development Cambridge Cognition Holdings plc
23-Apr-2024 MPE launches the Myeloma and AL Amyloidosis European Clinical Trial Navigator Myeloma Patients Europe (MPE)
21-Apr-2024 Agenda Announced for Semantic Data 2024: Taxonomy, Ontology, and Knowledge Graphs conference in London Henry Stewart Events
19-Apr-2024 Enhancing Care Coordination: The Role of Clinical Communication and Collaboration Solutions Markets and Markets